4DMedical inks GSK agreement, receives UK regulatory clearance
Make us a preferred source
Make us a preferred source on Google
The news: Medical imaging business 4DMedical has entered into a one-year agreement with pharma giant GlaxoSmithKline (GSK) to supply its functional lung imaging analytics to support pulmonary drug development.
4DMedical also said its flagship CT:VQ software has received certification for clinical use in the UK, expanding its European footprint following EU certification last month.
The context: Under its agreement with GSK, which commences 1 May, 4DMedical will supply advanced lung imaging biomarkers from its software analytics platform, enabling quantitative assessment of lung structure and function across clinical trial cohorts.
The contract value is commercially confidential and “not individually material”, the company said.
Meanwhile, 4DMedical said regulatory clearance for CT:VQ in the UK allows for “immediate commercial deployment” of the software across both public and private healthcare providers across the country.
CT:VQ has now received regulatory clearance in the US, EU, UK, Canada and New Zealand.
4DMedical will be included in the ASX 200 index for the first time on Monday.
What they said: “Our engagement with GSK demonstrates the growing importance of 4DMedical’s quantitative imaging analytics in pharmaceutical development,” said 4DMedical CEO Andreas Fouras.
“As biopharmaceutical companies seek more sensitive, reproducible endpoints to support respiratory drug development, our platform is increasingly well positioned to serve this expanding market alongside our established clinical business.”
The source: ASX
